Suppr超能文献

采用高灵敏度免疫放射分析法定量检测未经治疗及经治疗的真性红细胞增多症和原发性血小板增多症患者的血浆促红细胞生成素。

Plasma erythropoietin by high-detectability immunoradiometric assay in untreated and treated patients with polycythaemia vera and essential thrombocythaemia.

作者信息

Carneskog J, Kutti J, Wadenvik H, Lundberg P A, Lindstedt G

机构信息

Department of Medicine, Sahlgrenska University Hospital, University of Göteborg, Sweden.

出版信息

Eur J Haematol. 1998 May;60(5):278-82. doi: 10.1111/j.1600-0609.1998.tb01040.x.

Abstract

By using an immunoradiometric method with a stated detection limit of < or =1 IU/l (stated normal reference limit in adults 3.7-16 IU/l) we determined EDTA-plasma erythropoietin (EPO) in 58 patients with polycythaemia vera (PV) and 49 patients with essential thrombocythaemia (ET). At the time of blood sampling, 20 of the PV patients were newly diagnosed and untreated, 23 were treated by phlebotomy only, and 30 also received myelosuppressive treatment (with 32P, hydroxyurea or alpha-interferon). Of the ET patients 24 were untreated and 28 received myelosuppressive therapy. For comparison plasma EPO was also determined in 10 patients with pseudopolycythaemia (PP). In this latter group the results for plasma EPO agreed well with the cited normal reference limits. The majority of untreated PV patients (12/20) had undetectable plasma EPO concentration, and the remainder all had values below the lower normal reference limit. Plasma EPO in PV was not significantly influenced by phlebotomy therapy. Twelve of the 24 untreated ET patients (50%) had plasma EPO values below the reference interval (undetectable in 2 patients). The mean EPO concentration was significantly lower in PV patients receiving phlebotomy therapy than in patients with untreated ET. In the total material of PV and ET treated with myelosuppressive agents the PV patients showed significantly lower values for EPO concentration than did patients with ET. The present results support the view that EPO measurements by high-detectability methods are diagnostically useful and should be included in the panel of new criteria for the diagnosis of PV.

摘要

我们采用免疫放射分析法,其规定的检测限≤1 IU/l(成人规定的正常参考范围为3.7 - 16 IU/l),测定了58例真性红细胞增多症(PV)患者和49例原发性血小板增多症(ET)患者的乙二胺四乙酸(EDTA)血浆促红细胞生成素(EPO)。采血时,20例PV患者为新诊断且未治疗,23例仅接受放血治疗,30例还接受了骨髓抑制治疗(使用32P、羟基脲或α干扰素)。ET患者中,24例未治疗,28例接受了骨髓抑制治疗。为作比较,还测定了10例假性红细胞增多症(PP)患者的血浆EPO。在后一组中,血浆EPO结果与引用的正常参考范围相符。大多数未治疗的PV患者(12/20)血浆EPO浓度检测不到,其余患者的EPO值均低于正常参考范围下限。放血治疗对PV患者的血浆EPO无显著影响。24例未治疗的ET患者中有12例(50%)血浆EPO值低于参考区间(2例检测不到)。接受放血治疗的PV患者的平均EPO浓度显著低于未治疗的ET患者。在接受骨髓抑制药物治疗的PV和ET患者总体中,PV患者的EPO浓度值显著低于ET患者。目前的结果支持这样一种观点,即通过高检测性方法测量EPO在诊断上是有用的,应纳入PV诊断新标准的指标中。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验